Condition Guide

Peptides for Tendon & Ligament Injury

Tendon and ligament injuries heal slowly due to poor vascularization and low cellular turnover. Several peptides have been investigated for their ability to promote angiogenesis, collagen synthesis, and fibroblast migration at injury sites.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

How peptides help

BPC-157 upregulates VEGF and promotes angiogenesis; TB-500 modulates actin dynamics to enhance cell migration; GHK-Cu supports collagen synthesis. Animal data is robust for all three, but controlled human clinical trials are limited — use remains investigational.

Peptides researched for tendon & ligament injury

State of the evidence

Preclinical evidence is substantial (dozens of rodent studies). Human data is largely anecdotal or limited to case reports. Patients considering these compounds should work with informed clinicians.

Frequently asked

Is BPC-157 FDA approved for tendon healing?

No. BPC-157 is not FDA approved for any indication. It is studied primarily in animal models. Following the 2023 FDA Compounding Category 2 listing, it is restricted in the U.S.

How long does BPC-157 take to work for tendon injuries?

Animal studies show measurable healing improvements within 1-2 weeks. Human anecdotal reports vary widely. No rigorous dose-response data exist in humans.

Related articles & guides

Related conditions